estazolam PROSOM

Class: Benzodiazepine
FDA Indications: Short-term Treatment Of Insomnia
Off-Label Use: Catatonia
Prescribing
FDA Schedule IV
Forms: 1, 2mg tablet
Dose Range: 0.5-2 mg/day
Starting: 1 mg at bedtime; some patients may require 2 mg
Stopping: Abrupt discontinuation should be avoided. Daily dose may be decreased by 0.5 mg q3 days; however, some patients may require a slower reduction.

NAMI drug fact sheet

Precautions
Serious Side Effects: Overdose can result in hypotension, respiratory depression, and coma
Side Effects: sedation/somnolence, dizziness, confusion, disequilibrium, ataxia, lightheadedness, weakness/asthenia, decreased libido, dysarthria, constipation, increased appetite, weight gain
Pharmacodynamics
1° MOA: GABAAR PAM
Target: GABAA: α1, γ2, α3 (high); α2 (weak)
Pharmacokinetics
t½: 18 (10-24)° TMAX:
Absorption Rate: Fast
Lipid Solubility: Low-moderate
Substrate of: 3A4
Inhibits: ∅ ; Induces:
Active Metabolites:
DDIs
Misc
  • - Its long t½ makes it helpful for patients with late-insomnia, i.e. early morning awakening, but for the same reason has a liability for producing a hangover effect the morning after
Special Populations

Category X—Human Data Suggest Risk in 1st and 3rd Trimesters

No reports describing the use of estazolam in human pregnancy have been located. The effects of this drug on the fetus should be similar to other benzodiazepines. Maternal use near delivery may potentially cause neonatal motor depression and withdrawal.

0.5-1 mg at bed time. Initiate at lower doses for small elderly or debilitated patients

No adjustment provided in package insert; use with caution


No adjustment provided in package insert; use with caution

logo

Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated July 08 2018 15:58:23. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.